In accordance with Section 3 of the Articles of Association of Orion Corporation, 135,000 A shares have been converted into 135,000 B shares. The conversion has been entered into the Trade Register on 9 December 2015.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 38,906,154 A shares and 102,351,674 B shares.
Orion Corporation
| Olli Huotari SVP, Corporate Functions | Jari Karlson CFO |
Contact person:
Tuukka Hirvonen, Communications Manager, IR & Financial Communications
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.